Akari Therapeutics, Plc Gains 45.96%

Wed, Sep 24, 2025 at 07:51 PM

Akari Therapeutics, Plc (AKTX:NASDAQ) jumped higher at $1.11, representing a gain of 46%. On Wed, Sep 24, 2025, AKTX:NASDAQ touched a New 2-Week High of $1.11. The stock appeared on our News Catalysts scanner on Wed, Sep 24, 2025 at 09:38 AM in the 'BIOTECH' category. From Wed, Sep 10, 2025, the stock recorded 50.00% Up Days and 36.36% Green Days

About Akari Therapeutics, Plc (AKTX:NASDAQ)

Akari Therapeutics PLC is a biopharmaceutical company in clinical stage. It is focused on developing inhibitors of acute and chronic inflammation which includes the complement system, the bioamine system and the eicosanoid system.

Top 10 Gainers:

uniQure N.V. (QURE:NASDAQ), 247.73%
SHF Holdings, Inc. (SHFS:NASDAQ), 123.01%
Smart for Life, Inc. (SMFL:NASDAQ), 100%
Lithium Americas Corp. (LAC:NYSE), 95.77%
RedCloud Holdings plc (RCT:NASDAQ), 64.71%
ClearPoint Neuro, Inc. (CLPT:NASDAQ), 58.55%
TNF Pharmaceuticals, Inc. (TNFA:NASDAQ), 48.15%
Soluna Holdings, Inc. (SLNH:NASDAQ), 47.68%
Akari Therapeutics, Plc (AKTX:NASDAQ), 45.96%
Aqua Metals, Inc. (AQMS:NASDAQ), 44.94%